Atriva Therapeutics
Therapies against viral infections.

First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza.

Great potential against a wide variety of respiratory viruses due to immunomodulating and antiviral activity of ATRIVA’s lead product zapnometinib (pINN). Phase I clinical trial successfully completed, RESPIRE (a Phase II clinical trial in COVID-19) started patient enrolment in April 2021. A Phase II study in influenza is currently planned.

Stay informed on Atriva Therapeutics

Atriva Therapeutics kann dank Fördermitteln COVID-19-Medikament schneller entwickeln
Das biopharmazeutische Unternehmen Atriva Therapeutics GmbH, ein Vorreiter bei der Entwicklung von Therapien zur Behandlung von viralen Infektionen, hat sich Fördermittel des Bundes gesichert.
Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding
Atriva Therapeutics GmbH, a company that is pioneering the development of therapies for the treatment of viral infections, has secured up to €11.4 million in federal funding.
Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19
Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, announced today that the first patient was enrolled in its Phase II RESPIRE1 trial in COVID-19.
Atriva Therapeutics Announces Changes to Management in COVID-19
Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, today announced two changes to its management team.
Atriva Therapeutics Announces Changes to Advisory Board
Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced changes to its Advisory Board.
Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in Berlin
Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced today approval from the German Federal Institute for Drugs and Medical Devices (Bundesinstitut fĂĽr Arzneimittel und Medizinprodukte, BfArM) to initiate a pivotal Phase II clinical study with ATR-002 to treat hospitalized patients with moderate to severe COVID-19.
Initiative BEAT-COV fordert UnterstĂĽtzung fĂĽr Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente
„Wir können lebenswichtige Medikamente zur Behandlung von COVID-19-Patienten zur Verfügung stellen, aber wir benötigen signifikante Unterstützung bei der Finanzierung der Entwicklungs- und Produktionskosten – jetzt!“
Germany: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment
The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses.
Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan
Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.
Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target
Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the publication of in vitro results by Atriva Co-founder Prof. Stephan Ludwig.